| ID | 1173 |
| Name of the vaccine | VLA15 |
| Microbe | Bacteria |
| Disease name | Lyme disease (Lyme borreliosis) |
| Name of bacteria | Borrelia burgdorferi |
| Type of vaccine | Recombinant |
| Nucleic acid content | DNA |
| Age | 5 to 65 years |
| Description of the vaccine | Multivalent recombinant OspA (Outer Surface Protein A) based vaccine. |
| Name of the manufacturer | Valneva Austria GmbH and Pfizer |
| Name of the manufacturing country | United States |
| Year of manufacture | 2026 |
| Clinical Phase status | Clinical - Phase 2 |
| Bacterial strain | Gram-negative spirochete bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Three (month 0-2-6) or two (month 0-6) vaccinations. |
| Mechanism of action | Targets the outer surface protein A (OspA) of the bacteria. |
| Route of administration | Intramuscular |
| Indications | Protects from six serotypes of Borrelia. |
| Export | NA |
| Approval | NA |
| Adjuvant | Alum |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | Yes (from the bite of infected blacklegged ticks) |
| PubMed identifier | NA |
| Clinical trial number | NCT04801420 |
| Reference | https://www.clinicaltrialsarena.com/news/pfizer-valneva-lyme-disease/ |
| Other name | NA |
| Additional Links | NA
|